CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new method for delivering messenger RNA to immune cells using apolipoprotein nanoparticles. By creating a cost-effective in vivo CAR T cell therapy, it aims to expand cancer treatment options beyond hematological malignancies and improve accessibility for various cancer types.
Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment.
Nevertheless, CAR T cell therapy is clinically limited to hematological malignancies and hampered by its complex and costly ex vivo manufacturing procedure.
To render this treatment cost-effective and available for diverse cancer types, in vivo CAR immune cell therapy strategies must be developed.
My group has established new apolipoprotein nanoparticle (aNP) platform technology for RNA delivery to immune cells.…
TECHNISCHE UNIVERSITEIT EINDHOVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
